Brief: Independent Data Safety Monitoring Board Recommends Appili Complete Phase 3 Avigan/Reeqonus Trial
17/05/2021 14:19
May 17 (Reuters) - Appili Therapeutics Inc APLI.TO :
* INDEPENDENT DATA SAFETY MONITORING BOARD RECOMMENDS APPILI
THERAPEUTICS COMPLETE ITS PHASE 3 AVIGAN®/REEQONUS™ TRIAL FOR
MILD-TO-MODERATE COVID-19 PATIENTS
* APPILI THERAPEUTICS INC - AIMS TO COMPLETE STUDY AND DATA
ANALYSIS IN Q3 2021 FOR PREVENTING SEVERE COVID-19 TRIAL
Source text for Eikon: ID:nPn6hYTrFa
Further company coverage: APLI.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Appili Therapeutics
See all newsBrief: Appili Therapeutics Announces Closing Of Second Tranche Of Non-Brokered Private Placement
Brief: Appili Therapeutics Closes First Tranche Of Non-Brokered Private Placement
Brief: Appili Therapeutics Announces Proposed Non-Brokered Private Placement
Brief: Appili Therapeutics Announces Formal Termination Of Arrangement Agreement With Aditxt
Brief: Appili Therapeutics Announces New Patents Granted For Commercial Stage Asset Likmez